Progressive and conservative Democratic lawmakers, as well as President Joe Biden, are in favor of authorizing federal officials to negotiate with drugmakers over what Medicare pays for at least some of the most expensive brand-name drugs and to base those prices on the drugs’ clinical benefits. Such a measure could put Republicans in the uncomfortable position of opposing an idea that most voters from both parties generally support.
Category: Cost and Quality
‘Painless’ Glucose Monitors Pushed Despite Little Evidence They Help Most Diabetes Patients
The numbers of people wearing these monitors are soaring as prices have fallen and device-makers promote them to doctors and patients. But few studies show the devices lead to better outcomes for the nearly 25 million Americans with Type 2 diabetes who don’t inject insulin to regulate their blood sugar.
KHN’s ‘What the Health?’: Expanding the ACA in an Unpredicted Way
Beyond the billions of dollars aimed squarely at the pandemic, the covid relief bill cleared by Congress this week includes significant changes to health policy. Among them are the first major expansions to the Affordable Care Act since its enactment 11 years ago and changes that could expand coverage for the Medicaid program. Tami Luhby of CNN, Alice Miranda Ollstein of Politico and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.